Postoperative Crohn’s Disease: Biologics Prevent Recurrence Before It Starts: AJG | September 2026

What Did the Study Find?

This study evaluated 231 patients after ileocolonic resection for Crohn’s disease, comparing postoperative biologic prophylaxis with no biologic therapy.

High-risk endoscopic recurrence (modified Rutgeerts ≥i2b) occurred in 42.3% without biologic prophylaxis.

Recurrence was substantially lower with anti-TNF therapy: 9.4%.

Rates were 10.0% with vedolizumab and 27.8% with ustekinumab.

After inverse-probability weighting, all three biologic strategies significantly reduced recurrence compared with no treatment.

These were observational treatment groups rather than randomized head-to-head comparisons.

Therefore, the numerical differences between biologics should not be interpreted as comparative superiority.

Why Does It Matter?

Crohn’s disease frequently recurs after apparently successful surgery. These findings reinforce the postoperative period as a window for prevention, rather than waiting for endoscopic recurrence before restarting advanced therapy.

GastroAGI Takeaway

Surgery removes diseased bowel—it does not remove Crohn’s disease. In patients at meaningful risk of postoperative recurrence, early biologic prophylaxis can substantially reduce high-risk endoscopic recurrence. Vedolizumab and ustekinumab provide additional preventive options when anti-TNF therapy is unsuitable or previously exhausted, but this study cannot determine which biologic is best.